Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission

ToLEDo trial (n=202 per protocol) failed to demonstrate non-inferiority for abatacept or tocilizumab tapering strategy in evolution of disease activity according to DAS44 (primary outcome) or for flare incidence or rate of structural damage progression during 2-year follow-up.

SPS commentary:

In the trial, patients were randomised to treatment maintenance at full dose or progressive injection spacing driven by the Disease Activity Score in 28 joints (DAS28) every 3 months up to biologics discontinuation.

Arthritis & Rheumatology